HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

B-cell lymphoma (clinical) — Clinical Guidelines

Overview

Primary mediastinal B-cell lymphoma (PMBCL) is an aggressive subtype of large B-cell lymphoma characterized by distinct clinical, histopathological, and molecular features. Despite its aggressive nature, PMBCL has a high cure rate with appropriate management 1.

Diagnosis

Clinical Presentation: Often presents with mediastinal mass and symptoms related to compression or invasion 1.

Imaging: Chest CT and PET scans essential for staging and assessing mediastinal involvement 1.

Biopsy: Histopathological examination required for definitive diagnosis 1.

Molecular Markers: Evaluate for specific genetic alterations (e.g., FOXP1 rearrangements) 1.

Flow Cytometry: Useful for initial immunophenotyping 7.

CSF Analysis: Flow cytometry recommended for detecting occult CNS involvement in high-risk cases 7.

Management

First-Line Treatment: Chemotherapy regimens such as EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) or escalated BEACOPP (bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, prednisone) followed by radiation therapy for localized disease 1.

Targeted Therapy: BTK inhibitors (e.g., ibrutinib, zanubrutinib, acalabrutinib) considered for relapsed or refractory cases, though monitor for bleeding risks 2.

CAR-T Therapy: Anti-CD19 CAR-T cells with human binding domains show promise in reducing neurotoxicity 4.

Immunoliposomes: Doxorubicin-loaded immunoliposomes targeted via anti-CD74 antibodies may enhance efficacy in specific cases 6.

Special Populations

Elderly Patients: Tailored treatment approaches considering comorbidities and frailty; less intensive regimens may be appropriate 5.

Comorbidities: Bleeding risk assessment crucial in patients receiving BTK inhibitors due to potential adverse events 2.

Key Recommendations

Use comprehensive staging with imaging (CT, PET) and molecular markers for accurate diagnosis and risk stratification 1. (Evidence: Strong)

Employ EPOCH or escalated BEACOPP chemotherapy regimens followed by radiation for localized PMBCL 1. (Evidence: Strong)

Incorporate flow cytometry for cerebrospinal fluid analysis in patients at high risk for CNS involvement 7. (Evidence: Moderate)

Monitor closely for bleeding complications when using BTK inhibitors, especially in elderly or comorbid patients 2. (Evidence: Moderate)

Consider tailored treatment strategies for elderly patients, balancing efficacy with tolerability 5. (Evidence: Moderate)

References

1 Renaud L, Donzel M, Decroocq J, Decazes P, Galtier J, Burroni B et al.. Primary mediastinal B-cell lymphoma (PMBCL): The LYSA pragmatic guidelines. European journal of cancer (Oxford, England : 1990) 2025. link 2 Li X, Shang N, Yan Q, Yue X, Liu Y, Zheng X. Investigating bleeding adverse events associated with BTK inhibitors in the food and drug administration adverse event reporting system (FAERS). Expert opinion on drug safety 2025. link 3 . IFITM3 Enhances PI3K Pathway Signaling to Promote B-cell Malignancies. Cancer discovery 2021. link 4 . Human Binding Domains Reduce Neurotoxicity of Anti-CD19 CAR-T Cells. Cancer discovery 2020. link 5 Tarella C, Arcaini L, Baldini L, Barosi G, Billio A, Marchetti M et al.. Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma). Clinical lymphoma, myeloma & leukemia 2015. link 6 Lundberg BB, Griffiths G, Hansen HJ. Cellular association and cytotoxicity of doxorubicin-loaded immunoliposomes targeted via Fab' fragments of an anti-CD74 antibody. Drug delivery 2007. link 7 Hegde U, Filie A, Little RF, Janik JE, Grant N, Steinberg SM et al.. High incidence of occult leptomeningeal disease detected by flow cytometry in newly diagnosed aggressive B-cell lymphomas at risk for central nervous system involvement: the role of flow cytometry versus cytology. Blood 2005. link 8 Abe M, Tominaga K, Wakasa H. Phenotypic characterization of human B-lymphocyte subpopulations, particularly human CD5+ B-lymphocyte subpopulation within the mantle zones of secondary follicles. Leukemia 1994. link 9 Farrell DJ, Bloxham CA, Lucraft HH. Multilobated B-cell lymphoma of the spleen. Postgraduate medical journal 1993. link

B-cell lymphoma (clinical)